Roila, Fausto
 Distribuzione geografica
Continente #
NA - Nord America 1.338
EU - Europa 991
AS - Asia 354
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.685
Nazione #
US - Stati Uniti d'America 1.325
IE - Irlanda 466
IT - Italia 233
SG - Singapore 159
HK - Hong Kong 139
FR - Francia 67
UA - Ucraina 64
SE - Svezia 52
CN - Cina 37
DE - Germania 31
FI - Finlandia 26
RU - Federazione Russa 16
BE - Belgio 14
CA - Canada 11
GB - Regno Unito 10
TR - Turchia 6
KR - Corea 4
AT - Austria 3
CH - Svizzera 3
BG - Bulgaria 2
JP - Giappone 2
MX - Messico 2
MY - Malesia 2
NL - Olanda 2
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
IN - India 1
IS - Islanda 1
PH - Filippine 1
QA - Qatar 1
UZ - Uzbekistan 1
VN - Vietnam 1
Totale 2.685
Città #
Dublin 466
Chandler 347
Hong Kong 139
Altamura 135
Princeton 130
Medford 127
Lawrence 124
Singapore 89
Los Angeles 37
Jacksonville 35
San Mateo 33
Redmond 26
Andover 25
Ann Arbor 25
San Paolo di Civitate 20
Perugia 16
Wilmington 16
Boardman 14
Brussels 14
Helsinki 11
Napoli 11
Houston 10
Ashburn 9
New York 9
Boydton 8
Huskvarna 7
Norwalk 7
Rome 7
Toronto 7
Des Moines 6
Shanghai 6
Istanbul 5
Chicago 4
Lappeenranta 4
Seoul 4
Woodbridge 4
Ancona 3
Auburn Hills 3
Beijing 3
Guangzhou 3
Hanover 3
Saint Petersburg 3
Akishima 2
Falls Church 2
Forlì 2
Montréal 2
Naples 2
Ostra Vetere 2
Padova 2
Paris 2
Reggio Emilia 2
Terni 2
Turin 2
Vienna 2
Amelia 1
Amsterdam 1
Angeles 1
Aprilia 1
Assisi 1
Asso 1
Bologna 1
Cairo 1
Cannock 1
Changsha 1
Chaoyang 1
Cheyenne 1
Cleveland 1
Doha 1
Esslingen am Neckar 1
Fairfield 1
Falkenstein 1
Frankfurt Am Main 1
Frankfurt am Main 1
George Town 1
Grosseto 1
Hanoi 1
Izmir 1
Keflavik 1
Kilburn 1
Lake Forest 1
Laurel 1
Lausanne 1
Ludwigshafen 1
Malmo 1
Mequon 1
Milan 1
Monmouth Junction 1
Montreal 1
Moscow 1
Mumbai 1
Philadelphia 1
Redwood City 1
San Jose 1
Sofia 1
Tappahannock 1
Trumbull 1
Verona 1
Watchung 1
Totale 2.023
Nome #
Primitive thyroid lymphomas 90
Invasive ductal carcinoma arising in ectopic breast tissue of the axilla. Case report and review of the literature 75
Linee guida per la gestione dei pazienti affetti da melanoma cutaneo 61
High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS) responsive to weekly paclitaxel (P) and trastuzumab (T) treatment. 5 National Congress of Medical Oncology, Rome, 21-24 October 2003. 57
Surgical treatment of primitive thyroid lymphoma 53
Supportive care in cancer—a MASCC perspective 48
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 46
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. 45
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 45
Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study 42
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 41
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 40
Prevention and treatment of pandemic influenza in cancer patients. 39
Renal malignant solitary fibrous tumor with single lymph node involvement: report of unusual metastasis and review of the literature. 39
Incidence, characteristics and treatment of fatigue in oncological cancer patients (PTS) in Italy: A cross-sectional study. 38
Raccomandazioni cliniche per il melanoma cutaneo 38
Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program 37
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy 37
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 37
Juvenile papillomatosis of the breast in young male: a case report 36
Optimal Management of Fatigue 35
NICSO: Network Italiano Cure di Supporto in Oncologia – Italian Network for Supportive Care in Oncology 32
Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients 32
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 31
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study 31
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment 30
Targeted therapy for advanced cutaneous melanoma 29
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study 29
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 29
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy 29
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines 29
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients 28
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 28
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 27
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 27
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 26
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 26
Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A plus C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study 26
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 25
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 25
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting 25
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 25
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 25
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy 24
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 24
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis 24
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 24
New antiemetic drugs 23
Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in italy: a cross-section study 23
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: A randomized, double-blind study 22
Prevalence and spectrum of brca germline variants in central Italian high risk or familial breast/ovarian cancer patients: A monocentric study 21
Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case 20
Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy 20
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 20
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 19
Chemotherapy-induced nausea and vomiting 19
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study 19
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron? Reply 19
Hepatitis B in immunosuppressed cancer patients:pathogenesis, incidence and prophylaxis 18
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 18
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 18
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines 18
Management of oral and gastrointestinal mucositis: ESMO Clinical Recommendations 17
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 17
Acute emesis: moderately emetogenic chemotherapy 17
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy 16
Colorectal cancer and cardiovascular diseases: Are we closing the gap between knowledge and action? 16
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference 16
Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use 15
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 15
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 15
Conflict of interest among Italian medical oncologists: A national survey 15
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients 15
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 15
A new payment-by-results method for determining the fair price of new oncological drugs 14
The cost of chemotherapy-induced nausea and vomiting in Italy 14
Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference 14
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life 14
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines 14
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review 14
Management of febrile neutropenia: ESMO Clinical Recommendations 14
MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update 13
Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines 13
Management of cancer pain: ESMO Clinical Practice Guidelines 13
Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines 13
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management 13
PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer 13
State of the art of antiemetic therapy 13
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 13
New anti-emetic treatments 12
Hematopoietic growth factors: ESMO Recommendations for the applications 12
Tackling Off-Label Use of Anticancer Drugs 12
Daily challenges in oncology practice. What do we need to know about antiemetics? 12
Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use 12
Hematopoietic growth factors: ESMO Recommendations for the applications 12
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting (Reprinted) 12
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference 12
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: A study from the programma Ricerca e Innovazione Emilia Romagna oncology research group 12
DOACs in patients with brain cancers: promising but still a long way to go 11
Fatigue, a major still underestimated issue 11
Totale 2.507
Categoria #
all - tutte 19.084
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.084


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202064 5 3 10 0 10 4 13 1 9 2 1 6
2020/2021138 1 8 7 14 36 8 10 1 23 10 16 4
2021/2022522 3 29 6 11 7 2 4 160 8 24 21 247
2022/20231.478 150 371 32 57 105 78 0 53 557 9 45 21
2023/2024585 28 47 25 14 10 2 128 13 39 40 107 132
2024/20257 7 0 0 0 0 0 0 0 0 0 0 0
Totale 2.844